Angelos M. Stergiou - 16 Jun 2026 Form 4 Insider Report for SELLAS Life Sciences Group, Inc. (SLS)

Reporting relationship: President and CEO, Director
Issuer ticker: SLS
Reported as of: 16 Jun 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 18 Jun 2026, 16:30:24 UTC
Prior SEC filing: 05 Dec 2025
Source filing: View source filing
Reporting owner signature: /s/ Kostantinos Skordalos, Power of Attorney For: Angelos M. Stergiou

Key filing fact

Angelos M. Stergiou filed Form 4 for SELLAS Life Sciences Group, Inc. (SLS) on 18 Jun 2026.

Key facts

This page summarizes Angelos M. Stergiou's Form 4 filing for SELLAS Life Sciences Group, Inc. (SLS).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 18 Jun 2026, 16:30.

Change

Previous filing in this sequence was filed on 05 Dec 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001724253 Primary reporting owner

Stergiou Angelos M.

Relationship: President and CEO, Director
Address: C/O SELLAS LIFE SCIENCES GROUP, INC.,, 7 TIMES SQUARE, SUITE 2503, NEW YORK
Signature: /s/ Kostantinos Skordalos, Power of Attorney For: Angelos M. Stergiou
Signature date: 18 Jun 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

SLS transaction

Common Stock

Award

Transaction value
Shares: +1,065,000
Change %: +153%
Price: $0.000000^*
Shares after: 1,759,183
Date: 16 Jun 2026
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The Reporting Person received an award of 1,065,000 restricted stock units on June 16, 2026, which shall vest as follows: (i) 25% on December 1, 2026 and (ii) 25% on each December 1 thereafter until fully vested, provided that the Reporting Person remains in service with the Issuer through each such vesting date.